Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Our vision is to be a world-class commercial biotechnology company. We believe that we can achieve this with an approach of focused excellence in everything that we do-in working efficiently, in making data-driven decisions quickly, and in advancing promising compounds rapidly. Already, we have built one of the most impressive oncology development pipelines in the biotechnology and pharmaceutical industries.
More >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.32
Change (%) Stock is Up 0.10 (3.11%)
Volume6,959,989
Data as of 04/16/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
03/25/14Exelixis Provides Update on Ongoing COMET-1 Phase 3 Pivotal Trial in Men with Metastatic Castration-Resistant Prostate CancerPrinter Friendly Version
03/25/14Exelixis Receives Approval for COMETRIQ® (Cabozantinib) in the European Union for Treatment of Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid CarcinomaPrinter Friendly Version
02/26/14Exelixis Announces Webcast of March 4 Presentation at the 34th Annual Cowen and Company Health Care ConferencePrinter Friendly Version
02/20/14Exelixis Announces Fourth Quarter and Full Year 2013 Financial ResultsPrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation2012 Annual Report (pdf)
Download Documentation2011 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.